Valuation: Kadimastem

Market Cap 57.15M 0 18.74M 16.44M 15.31M 14.08M 26.4M 1.79B 26.85M 182M 71.1M 888M 70.34M 68.82M 3.07B P/E 2026 *
-
P/E 2027 * -
Enterprise Value 57.15M 0 18.74M 16.44M 15.31M 14.08M 26.4M 1.79B 26.85M 182M 71.1M 888M 70.34M 68.82M 3.07B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
31.94%
Yield 2026 *
-
Yield 2027 * -
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-8.93% - - 19.38M
+0.14%-0.67%-0.88%+11.02% 47.74B
-2.24%+0.31%+393.45%+615.13% 39.98B
+1.40%+3.69%+12.21%+46.79% 36.23B
+13.94%+20.49%+22.85%+7.42% 35.59B
-0.73%+3.38%+4.94%+41.45% 27.91B
+0.40%-0.30% - - 16.71B
-3.12%+7.39%+26.03%+124.08% 16.45B
+2.39%-1.64%+4.74%+9.95% 13.21B
+6.79%+8.17%-4.97%-28.52% 12.93B
Average +1.90%+2.97%+57.30%+103.42% 27.42B
Weighted average by Cap. +2.10%+2.54%+76.11%+130.59%

Financials

2026 *2027 *
Net sales - -
Net income - -
Net Debt - -
Logo Kadimastem
NewcelX AG, formerly NLS Pharmaceutics AG, is a Switzerland-based company primarily engaged in the biotechnology industry. The Company focuses on the discovery and development of therapies for rare and complex central nervous system (CNS) disorders, including sleep and neurodevelopmental conditions. The Company offers products like Quilience, which is a clinical-stage pharmaceutical compound. It aims to support the treatment of narcolepsy by modulating monoamine neurotransmission and orexin receptor activity. The Company also develops product like Nolazol, a treatment candidate for Attention Deficit Hyperactivity Disorder (ADHD). The Company is a publicly traded company, listing on the NASDAQ.
Employees
11